Alerta

TUNABLE DARPIN-BASED AND/OR ANTI-ANGIOGENIC AND/OR IMMUNOMODULATORY NANOPARTICLE CONJUGATES, CELLULAR IMMUNOHERAPEUTICS, AND USES THEREOF

Resumen de: WO2025250839A1

Disclosed herein are nanoparticle conjugates (e.g., anti-angiogenic and/or immunomodulatory nanoparticle conjugates, e.g., high-affinity Designed Ankyrin Repeat Protein (DARPin)-based binders targeting one or more cancer and/or immune receptors). The nanoparticle conjugates are useful for therapeutics and/or diagnostics and have a diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution).

PHARMACEUTICAL COMPOSITION COMPRISING SIALIC ACID FOR TREATING DISEASES RELATED TO THE LUNG

Resumen de: WO2025250539A1

The present invention provides a pharmaceutical composition capable of delivering therapeutic agents such as nucleic acids to the lung via systemic administration to treat lung-related diseases. Said composition comprises a non-covalent complex formed by co-precipitating a sialic acid (SA) entity, a complexing agent, and a nucleic acid cargo.

CONTROLLED ASSEMBLY OF LIPID-BASED NANOPARTICLES FROM SURFACTANT MICELLES

Resumen de: WO2025250244A1

The disclosure provides particles, including anisotropic particles, and compositions, methods and kits thereof that are useful, e.g., for delivering an agent or in treating or preventing diseases, such as proliferative diseases. The disclosure also provides methods of preparing plurality of such particles and liposomes that provide control over size and morphology.

CANCER-TARGETING DRUG DELIVERY SYSTEM COMPRISING HEPARIN- AND PROTAMINE-BASED SELF-ASSEMBLED NANOPARTICLES

Resumen de: WO2025249682A1

The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.

METHOD FOR PRODUCING EXTRACELLULAR VESICLES FOR WOUND HEALING USING ELECTROPORATION

Resumen de: WO2025249687A1

The present invention relates to a method for producing extracellular vesicles into which a therapeutic gene is introduced by electroporation, a wound-healing pharmaceutical composition produced by the method, and a wound-healing pharmaceutical preparation or quasi-drug preparation comprising same as an active ingredient. The extracellular vesicles derived from mesenchymal stem cells (MSCs), fibroblasts, and colostrum, produced by the present method, are all non-cytotoxic, have excellent nucleic acid delivery efficiency, and thus allow for stable expression. In particular, by introducing a vascular endothelial growth factor (VEGF) gene, which is known to have a wound-healing effect, into extracellular vesicles derived from mesenchymal stem cells (MSCs), fibroblasts, and colostrum through electroporation, VEGF gene-introduced extracellular vesicles produced by the production method of the present invention can be used as a gene therapy agent for wound healing.

NOVEL CURCUMIN NANO-FORMULATION AND PROCESS FOR PREPARATION THEREOF

Resumen de: WO2025248298A1

The present invention provides nano-formulation of Curcumin having nano Curcumin content up to 10% w/w in formulation (up to 90 mg) with 100% solubility in water, - and particle size less than 100 nm with good bioavailability through enhanced permeability and stability, thereby increase in their effectiveness for various therapeutic uses. The nano-formulation of Curcumin is having low particle size and increased efficacy, stability against pH, light, temperature, and humidity.

IONIZABLE LIPID MOLECULE CONTAINING ARGININE STRUCTURE, LIPID NANOPARTICLES COMPRISING SAME, AND USE THEREOF

Resumen de: WO2025245869A1

The present invention relates to an ionizable lipid molecule containing an arginine structure, lipid nanoparticles comprising same, and use thereof. Specifically, provided are an ionizable lipid molecule represented by formula (1) containing a structure of arginine and a derivative thereof, lipid nanoparticles comprising same, a preparation method therefor, and use thereof. Compared with ionizable lipid molecules conventionally used in the art, the lipid nanoparticles prepared from the ionizable lipid molecule represented by formula (1) of the present invention can achieve highly efficient delivery and expression of nucleic acids.

METHOD FOR PRODUCING A HYDROGEL-TYPE MEDICAL DEVICE CONTAINING EMBEDDED COPPER NANOPARTICLES

Resumen de: WO2025245652A1

Disclosed is a method for producing a hydrogel-type medical device, which comprises producing, in advance, copper nanoparticles coated with high-molecular-weight chitosan; and incorporating the particles during the final minutes of a step of crosslinking, which allows the coating to remain on the nanoparticles, preventing the dissolution thereof, and the nanoparticles to be uniformly incorporated into the latticed formation of the hydrogel. Also disclosed are the hydrogel and the use thereof in different types of wounds, burns and ulcerations.

POLYMER NANOPARTICLE COMPOSITIONS FOR NON-VIRAL GENE DELIVERY

Resumen de: WO2025250979A1

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

PROCESS FOR PREPARATION OF TARGETED LIPID NANOPARTICLES

Resumen de: WO2025250906A1

The present invention relates to processes for preparing lipid nanoparticles having an antibody or fragment antibody binding region.

SOLID LIPID NANOPARTICLES FOR ENCAPSULATION AND DELIVERY OF BIOACTIVE COMPOUNDS AND METHODS OF MAKING THE SAME

Resumen de: US2025367132A1

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

アミド及びエステル官能基を有する脂質及びその製造方法

Resumen de: CN120019041A

The present invention relates to a lipid having an amide functional group and an ester functional group and a method for preparing the same, and more particularly, to an ionized lipid which forms a complex with an anionic drug, and which can be used for drug delivery due to a specific structure having an amide functional group and an ester functional group, and a method for preparing the same.

ＴＧＦ－β１ワクチン

Resumen de: MX2025005144A

The present invention relates to novel polypeptides, which are derived from transforming growth factor beta 1 (TGFβ1; TGFb-1) as well as polynucleotides encoding such polypeptides and compositions comprising such peptides. The present invention is further concerned with ways to increase the selectivity of the immune response to TGFb-1. The invention also concerns uses, and methods of using, said polypeptides, polynucleotides, and compositions.

脂質化合物およびその使用

Resumen de: US2025367129A1

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

ポリオキシアルキレンがＣ１～Ｃ３－アルキルオキシメチル側鎖を有するポリ（エチレンオキシド）である、ポリオキシアルキレン－１，２－ジミリストイル－グリセロール化合物

Resumen de: MX2025005575A

The present invention refers to novel polyoxyalkylene based compounds and their manufacturing method as well as compositions comprising at least one novel polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.

浮腫性線維硬化性脂肪組織異常を治療及び／又は予防するための方法

Resumen de: CA3272967A1

It provides a method for treating and/or preventing edematous fibrosclerotic panniculopathy (EFP) in a subject in need thereof. The method includes administering to the subject an effective amount of a pharmaceutical composition. The pharmaceutical composition includes a plurality of amphiphilic nanoparticles having one or more active ingredients encapsulated therein. Each of the amphiphilic nanoparticles is formed by a non-ionic surfactant, a polymeric carrier, or a lipid carrier. The hydrophilic-lipophilic balance (HLB) value of the non-ionic surfactant is greater than 9. The pharmaceutical composition is administered via a parenteral route by an injection, a microneedle, or an implant, or via topical administration or transdermal administration.

Ｃ１～Ｃ３－アルキルオキシメチル側鎖を有するポリ（エチレンオキシド）とコンジュゲートした脂質

Resumen de: MX2025005655A

The present invention refers to novel polyoxyalkylene based compounds and their manufacturing method as well as compositions comprising at least one novel polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.

METHODS OF MAKING AND ISOLATING CIRCULAR RNAS AND CIRCULAR RNA COMPOSITIONS

Resumen de: AU2024211148A1

Provided herein is a method of making circular RNA, a method of isolating circular RNA and compositions comprising circular RNA.

COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER

Resumen de: EP4656628A1

An object of the present invention is to provide a compound or a salt thereof constituting lipid composition that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide a lipid composition, a pharmaceutical composition, and a delivery carrier, using the compound or a salt thereof. According to the present invention, a compound represented by Formula (1) or a salt thereof is provided.In the formula, R¹, R², R³, and R⁴ each independently represent a hydrogen atom or a hydrocarbon group having 1 to 24 carbon atoms, which may be substituted, R⁵ and R⁶ each independently represent a hydrocarbon group having 1 to 18 carbon atoms, which may be substituted, R⁷, R⁸, and R⁹ each independently represent a hydrocarbon group having 2 to 8 carbon atoms, and R⁵ and R⁶, or R⁵ and R⁷, may be combined to form a 4- to 7-membered ring.

A METHOD FOR THE PRODUCTION OF POLYPRENOL NANOEMULSION AND THE POLYPRENOL NANOEMULSION OBTAINED

Resumen de: WO2025034098A1

A method for the production of a polyprenol nanoemulsion involving: - mixing of polyprenols with divalent alcohol in a mass ratio of 1:0.5-2; - the addition of an emulsifier containing polyethylene glycol sorbitan monooleate at a proportion of 50-100% of the mixture of polyprenols and divalent alcohol by mass; - mixing and heating of the resulting mixture for 5-15 minutes at a temperature of 70-80 °C; - dissolving NaCI in water, adding glucose, previously prepared phosphate buffer solution with the pH 6.88 and divalent alcohol, and mixing; - mixing and heating of the resulting aqueous mixture for 5-15 minutes at a temperature of 70-80 °C. A polyprenol nanoemulsion comprising by mass%: polyprenols 2.5-10; emulsifier that contains polyethylene glycol sorbitan monooleate 7-8; divalent alcohol 8-12; NaCI 0.9; glucose 5; phosphate buffer solution with pH 6.88 8-12; water, the rest.

NANOPARTICLES FOR THE DELIVERY OF AN ACTIVE AGENT

Resumen de: EP4656180A1

Nanoteilchen (1) zur Verabreichung zumindest eines Wirkstoffs (4), umfassend einen magnetisierbaren Kern (2), wobei der Kern (2) eine Ummantelung (3) aus einem Polyphosphat aufweist, wobei die Ummantelung (3) den Kern (2) vollständig umschließt, dadurch gekennzeichnet, dass die Ummantelung (3) mit einem Wirkstoff (4) versetzt ist.

INJECTABLE COMPOSITIONS OF EMD FRACTION B

Resumen de: EP4656213A1

The present invention relates to a pharmaceutical, dental and/or cosmetic composition comprising purified and/or isolated matrix derivative (EMD) proteins and a suitable pharmaceutical carrier, characterized in that the purified and/or isolated enamel matrix derivative (EMD) proteins comprised in said composition have a predominant MW of between 10-13kDa and an aggregation particle size of between 20-200 nm at Room Temperature (RT) and a pH of between 6.0-7.5.Said pharmaceutical, dental and/or cosmetic composition is disclosed for use in healing, restoration, enhancement and/or promotion of soft tissue in the oral cavity and/or craniomaxillofacial complex (CMF), in particular for use in treating patients suffering from a gingival deficiency and/or disorder. Preferably, the composition of the invention is administered via injection into the soft tissue in the oral cavity and/or the craniomaxillofacial complex (CMF) of the patient.

A MODIFIED LIPID COMPOSITION AND USES THEREOF

Resumen de: AU2024212425A1

Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, glucosyl cholesterol; and modified by (b) an ionizable lipid. The disclosure also includes a method for making a modified lipid composition, comprising reconstructing (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, and/or glucosyl cholesterol in the presence of (b) an ionizable lipid, to produce the modified lipid composition, and loading into the modified lipid composition with one or more heterologous functional agents.

MIXTURES OF LIPID NANOPARTICLES AND CELL PENETRATING PEPTIDES

Resumen de: WO2024156871A1

The present invention provides for a membrane-permeable construct for transport of cargo across a lipid membrane and subsequent delivery of cargo into cells as well as in vivo, wherein the construct comprises a Lipid nanoparticle (LNP) complexed with known or proprietary cell penetrating peptide (CPP) embedding the cargo molecule.

一种可电离阳离子脂质化合物及其制备方法和应用

Nº publicación: CN121045013A 02/12/2025

Solicitante:

汉信生物科技（苏州）有限公司

Resumen de: CN121045013A

本发明涉及一种可电离阳离子脂质化合物及其制备方法和应用，涉及药用化合物技术领域，本发明公开了一种新结构的可电离阳离子脂质化合物，该可电离阳离子脂质化合物与目前最高效的脂质纳米粒子(DLin‑MC3‑DMA)相比，本发明公开的脂质纳米粒子不仅制备过程简单，反应条件温和，产率高，成本低，而且递送效率更高。